Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pharmacogenomics, lipid disorders, and treatment options.

Gryn SE, Hegele RA.

Clin Pharmacol Ther. 2014 Jul;96(1):36-47. doi: 10.1038/clpt.2014.82. Epub 2014 Apr 10. Review.

PMID:
24722394
2.

Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.

Schmitz G, Schmitz-Madry A, Ugocsai P.

Curr Opin Lipidol. 2007 Apr;18(2):164-73. Review.

PMID:
17353665
3.

Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?

Alfonsi JE, Hegele RA, Gryn SE.

Curr Atheroscler Rep. 2016 May;18(5):24. doi: 10.1007/s11883-016-0573-6. Review.

PMID:
26993470
4.

Pharmacogenomics of cholesterol-lowering therapy.

Schmitz G, Langmann T.

Vascul Pharmacol. 2006 Feb;44(2):75-89. Epub 2005 Dec 5. Review.

PMID:
16337220
5.

[Combined treatment: regimens, indications and safety profile].

Muñiz Grijalvo O, Villar Ortiz J.

Clin Investig Arterioscler. 2013 Jul-Aug;25(3):140-5. doi: 10.1016/j.arteri.2013.06.003. Epub 2013 Jul 21. Spanish.

PMID:
23880257
6.

Pharmacogenomics of lipid-lowering therapies.

Hu M, Tomlinson B.

Pharmacogenomics. 2013 Jun;14(8):981-95. doi: 10.2217/pgs.13.71. Review.

PMID:
23746191
7.

[Pleiotropic effects of statins on endothelium and signaling mechanisms].

Shiota M, Izumi Y, Nakao T, Iwao H.

Nihon Yakurigaku Zasshi. 2006 Sep;128(3):161-6. Review. Japanese. No abstract available.

PMID:
16971779
8.

Current and future options for lipid-lowering therapy beyond statins.

Gouni-Berthold I.

Curr Pharm Des. 2013;19(17):3072-3. No abstract available.

PMID:
23317406
9.

Use of lipid-lowering agents (statins) during pregnancy.

Hosokawa A, Bar-Oz B, Ito S.

Can Fam Physician. 2003 Jun;49:747-9.

10.

Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey.

Charles-Schoeman C, Amjadi SS, Paulus HE; International Myositis Assessment and Clinical Studies Group.

Clin Rheumatol. 2012 Aug;31(8):1163-8. Epub 2012 Apr 21.

PMID:
22526479
11.

[Lipid lowering therapy in geriatric patients].

Lechleitner M.

Z Gerontol Geriatr. 2013 Aug;46(6):577-85; quiz 586-7. doi: 10.1007/s00391-013-0516-6. German.

PMID:
23955359
12.

Pharmacogenetics of statins therapy.

Puccetti L, Acampa M, Auteri A.

Recent Pat Cardiovasc Drug Discov. 2007 Nov;2(3):228-36. Review.

PMID:
18221122
13.

[Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors].

Rosendo AB, Dal-Pizzol F, Fiegenbaum M, Almeida Sd.

Arq Bras Endocrinol Metabol. 2007 Jun;51(4):520-5. Review. Portuguese.

14.

Statins and coronary artery disease: clinical evidence and future perspective.

Biasucci LM, Stefanelli A, Biasillo G.

Minerva Cardioangiol. 2012 Apr;60(2):147-56. Review.

PMID:
22495163
15.

Lipid-lowering agents.

Ewang-Emukowhate M, Wierzbicki AS.

J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):401-11. doi: 10.1177/1074248413492906. Epub 2013 Jun 27. Review.

PMID:
23811423
17.

[Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].

Kłosiewicz-Latoszek L, Respondek W, Białobrzeska-Paluszkiewicz J, Grzybowska B, Jakóbisiak-Ostasz B, Stolarska I.

Pol Merkur Lekarski. 2003 Jul;15(85):42-6. Polish.

PMID:
14593958
18.

Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?

Hochholzer W, Giugliano RP.

Curr Atheroscler Rep. 2013 Jan;15(1):290. doi: 10.1007/s11883-012-0290-8. Review.

PMID:
23242605
19.

Lipid-lowering drug therapy in elderly patients.

Berthold HK, Gouni-Berthold I.

Curr Pharm Des. 2011;17(9):877-93. Review.

PMID:
21418034
20.

Pharmacologic interactions of multidrug therapy for dyslipidemia.

Mehta N, deGoma EM.

Curr Atheroscler Rep. 2013 Feb;15(2):303. doi: 10.1007/s11883-012-0303-7. Review.

PMID:
23299643

Supplemental Content

Support Center